Clinical Trial: Effects of Herbal Antioxidants on Cardiovascular Disease in Older Blacks

This study is no longer recruiting patients.

Sponsors and Collaborators: National Center for Complementary and Alternative Medicine (NCCAM)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Aging (NIA)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)

Purpose

The purpose of this study is to compare an herbal supplement, nonfood-derived vitamins, and placebo for the care of cardiovascular disease in high risk older African Americans.

Condition Treatment or Intervention Phase
Cardiovascular Diseases
 Drug: MAK
 Drug: Vitamin Supplements
Phase II

MedlinePlus related topics:  Heart Diseases;   Vascular Diseases

Study Type: Interventional
Study Design: Treatment, Randomized

Further Study Details: 

Expected Total Enrollment:  138

Older African Americans suffer from disproportionately high rates of cardiovascular disease (CVD) morbidity and mortality. In response to the health disparity between older African Americans and whites, national mandates have called for new research on innovative approaches to CVD prevention in this high risk population. Oxidative stress has recently been implicated in the pathogenesis of atherosclerotic CVD. Available evidence from epidemiological studies, clinical trials, and laboratory mechanistic studies indicate that antioxidant interventions may be useful in the prevention and treatment of atherosclerotic CVD in high risk older populations. Furthermore, it has been hypothesized that dietary or food sources of antioxidant nutrients may be more clinically effective than conventional nonfood-derived vitamin supplementation. Surveys indicate relatively high rates of complementary and alternative medicine (CAM) use, including herbal medicines, in older African Americans. Yet, with the exception of the previous clinical trials of the present Center team, there have been few controlled studies on CAM therapies in older African Americans and no previous controlled studies on efficacy and mechanisms of herbal antioxidants for the prevention of CVD in this high risk population. Preliminary studies have found that a CAM herbal preparation (MAK) derived from traditional Vedic medicine demonstrates potent antioxidant and anti-atherogenic effects in laboratory and pilot human studies. This study will evaluate the effects of this traditional CAM herbal preparation in older African Americans.

This will be a controlled clinical trial at field site, Howard University Medical Center in Washington, DC, involving 138 older African American men and women (55 years of age and older) with documented atherosclerotic CVD who will be randomized to supplementation with either the traditional CAM herbal preparation (MAK 4+5), conventional vitamin cocktail (E+C) or placebo for 12 months. Clinical and mechanistic outcomes include carotid artery atherosclerosis (IMT), endothelial dysfunction (brachial artery reactivity), oxidized LDL, traditional CVD risk factors (BP, lipids, diet, exercise, smoking, weight) and quality of life. Participants will continue usual care. The results of this clinical study will provide much needed understanding of the basic and clinical effects of a traditional herbal antioxidant preparation on pathophysiological mechanisms of atherosclerotic CVD in this high risk group. This will facilitate translation of research findings on CAM into clinical practice for prevention of disease in this underserved and understudied population of high risk older African Americans.

Eligibility

Ages Eligible for Study:  60 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

  • African American (self-identified)
  • Atherosclerotic coronary heart disease (CHD)defined by documented clinical history of myocardial infarction, coronary revascularization procedure (CABG, PTCA), or coronary angiography demonstrating at least one coronary artery with >50% stenosis
  • High risk for CVD, defined as >=2 on Framingham/ATP III risk factor scale
  • Informed consent
  • Written permission of participant's referring physician

Location Information


District of Columbia
      Howard University Medical Center, Washington, DC,  District of Columbia,  United States

Iowa
      Maharishi University of Management, Fairfield,  Iowa,  52557,  United States

Study chairs or principal investigators

Robert H. Schneider,  Principal Investigator,  Center for Health and Aging Studies   

More Information

Study ID Numbers:  1 P50 AT00082-01P3; 1-P50AT00082-01; 5-P50AT00082-02
Record last reviewed:  March 2004
Last Updated:  October 13, 2004
Record first received:  February 2, 2001
ClinicalTrials.gov Identifier:  NCT00010725
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005